Yüklüyor......
Olaparib in hormone receptor-positive, HER2-negative metastatic breast cancer with a somatic BRCA2 mutation
The oral poly(adenosine diphosphate-ribose) polymerase inhibitor olaparib is approved for the treatment of patients with human epidermal growth factor 2-negative (HER2−) metastatic breast cancer (mBC) and a germline breast cancer susceptibility gene (BRCA) mutation who have been treated with chemoth...
Kaydedildi:
| Yayımlandı: | Ther Adv Med Oncol |
|---|---|
| Asıl Yazarlar: | , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
SAGE Publications
2021
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8024449/ https://ncbi.nlm.nih.gov/pubmed/33868464 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/17588359211006962 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|